Table 3.
MicroRNA alteration in various human cancers
| MicroRNAs | Target Gene(s) | Cancer Type | Alterations |
|---|---|---|---|
| miR-127 | Bcl-6 | bladder cancer | upregulation |
| miR-124 | CDK6 | colon cancer | upregulation |
| miR-223 | NFI-A, MEF2C | acute myeloid leukemia | upregulation |
| miR-34b/34c | p53 network, CDK6, E2F3 | colon cancer | upregulation |
| miR-17, miR-92 | c-MYC | lung cancer | upregulation |
| miR-372,miR-373 | RAS, p53 ,CD44 | testicular germ cell tumor and breast cancer | upregulation |
| miR-21 | PDCD4,PTEN,TPM1,RECK, TIMP3, BCL2 | glioblastoma, breast, lung, prostate, colon and cervical cancer | upregulation |
| miR-155 | RHOA | Burkitt's lymphoma, breast ,colon, and lung cancers | upregulation |
| miR-146 | NF-κB | breast, pancreas and prostate cancers | upregulation |
| miR-92b | PRMT5 | brain primary tumors | upregulation |
| miR-520 | CD44 | breast cancer | upregulation |
| miR-10b | HOXD10 | metastatic breast cancer | upregulation |
| miR-9 | CDH1 | breast cancer | upregulation |
| miR-127, miR-199a | BCL6, E2F1 | cervical cancer | upregulation |
| miR-421 | CBX7, RBMXL1 | gastric cancer | upregulation |
| miR-1228,miR-195, miR30b, miR-32, miR345 | CDKN2A,NF2,andJUN | Malignant mesothelioma (MM) | upregulation |
| miR-190, miR-196 | HGF | pancreatic cancer | upregulation |
| miR-125 | AKT, ERBB2-4, FGF, FGFR, IGF, MAPKs, MMP11, SP1, TNF, VEGF | breast | upregulation |
| miR-126 | CRK1,PIK3R2,SPRED1, VCAM1 | breast and lung cancer | downregulation |
| miR-146a, miR-146b | ROCK1, IRAK1,TRAF6 | prostate cancer and papillary thyroid carcinomas | downregulation |
| miR-340, miR-421, miR-658 | MYC, RB, PTEN | lymph node metastasis and gastric cancer | downregulation |
| let-7a-3 | RAS, IGF-II | lung and ovarian cancer | downregulation |
| miR-221, miR-222 | CDKN1C/P57 and CDKN1B/P27 | hepatocellular carcinoma | downregulation |
| miR-9 | NF-κB | ovarian and lung cancer | downregulation |
| miR-218, miR-145 | PXN | breast, lung and prostate cancer | downregulation |
| miR-25, miR-32, miR-142 | ITGAα1 | lung cancer and solid tumor | downregulation |
| miR- 124, miR-183 | ITGBβ1 | lung cancer | downregulation |
| miR-143 | ERK5 | cervical cancer | downregulation |
| miR-372, miR-373 | LATS2 | testicular germ cell cancer | downregulation |
| miR-181 | VGFR | lung cancer | downregulation |
| miR-370 | MAP3K8 | MzChA-1, KMCH-1, cholangiocarcinoma | downregulation |
| miR-342 | ER, PR and HER2 | breast and colon cancer | downregulation |
| miR-145 | ER | colon and breast cancer | downregulation |
| miR- 124, miR-183 | ITGB1 β | lung cancer | downregulation |
CDK6, cyclin D kinase 6; MEF2C, myocyte enhancer factor 2C; NFIA, Nuclear factor 1 A-type; p53, tumor protein 53; RAS, Rat Sarcoma; CD44, cluster differentiation 44; PDcD4, programmed cell death 4; TPM1, tropomyosin 1; PTEN, phosphatase and tensin homologue; BCL2, B-cell lymphoma 2 protein; RECK, reversion Inducing cysteine rich protein kazal motif; ROHA, ras homolog gene family member A; NF-κB, nuclear factor-κappaB; PRNT5, protein arginine N-methyltransferase 5; HOXD10, homeobox D10; CDH1, Cadherin-1; CBX7, chromobox 7; RBMX L1, RNA binding motif protein X-linked; CDNK2A, cyclin-dependent kinase inhibitor 2A; NF2, neurofibromatosis, type 2; HGF, hepatocyte growth factor; ERBB2-4′ or (HER4), human epidermal growth factor Receptor 4; JUN, janus N-terminal kinases; FGFR, fibroblast growth factor receptor; MAPKs, mitogen-activated protein kinase; MMP11, matrix metalloproteinase11; VEGF, vascular endothelial growth factor; TNFα, tumor necrosis factor-alpha; CRK1, Cdc2-related kinase1; PIK3R2, phosphatidylinositol 3-kinase regulatory subunit beta; SPRED1,sprouty-related, EVH1 domain containing 1; VCAM, vascular cell adhesion molecule; ROCK1, rho-associated, coiled-coil containing protein kinase 1; IRAK1, interleukin-1 receptor associated kinase-1; TRAF6, TNF receptor associated factor 6; Rb, retinoblastoma; IGF-II, insulin-like growth factor 2; PXN, paxilin; ITGβ1, integrin beta-1; ERK5, extracellular signal-regulated kinase 5; LATS2, large tumor suppressor homolog 2; ER, estrogen receptor; PR, progesterone receptor.